| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Cardiology and Pneumonology, Campus Benjamin Franklin, Charité-University Medicine, Free University of Berlin;
* Department of Biophysics, Universidade Federal de São Paulo, São Paulo, Brazil; and
Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
1Correspondence: Charite-University Medicine, Campus Benjamin Franklin, Department of Cardiology and Pneumonology, Free University of Berlin, Hindenburgdamm 30, D-12220 Berlin, Germany. E-mail: ctschoepe{at}yahoo.com
Diabetic cardiomyopathy includes fibrosis. Kallikrein (KLK) can inhibit collagen synthesis and promote collagen breakdown. We investigated cardiac fibrosis and left ventricular (LV) function in transgenic rats (TGR) expressing the human kallikrein 1 (hKLK1) gene in streptozotocin (STZ) -induced diabetic conditions. Six weeks after STZ injection, LV function was determined in male Sprague-Dawley (SD) rats and TGR(hKLK1) (n=10/group) by a Millar tip catheter. Total collagen content (Sirius Red staining) and expression of types I, III, and VI collagen were quantified by digital image analysis. SD-STZ hearts demonstrated significantly higher total collagen amounts than normoglycemic controls, reflected by the concomitant increment of collagen types I, III, and VI. This correlated with a significant reduction of LV function vs. normoglycemic controls. In contrast, surface-specific content of the extracellular matrix, including collagen types I, III, and VI expression, was significantly lower in TGR(hKLK1)-STZ, not exceeding the content of SD and TGR(hKLK1) controls. This was paralleled by a preserved LV function in TGR(hKLK1)-STZ animals. The kallikrein inhibitor aprotinin and the bradykinin (BK) B2 receptor antagonist icatibant reduced the beneficial effects on LV function and collagen content in TGR(hKLK1)-STZ animals. Transgenic expression of hKLK1 counteracts the progression of LV contractile dysfunction and extracellular matrix remodeling in STZ-induced diabetic cardiomyopathy via a BK B2 receptor-dependent pathway.—Tschöpe, C., Walther, T., Königer, J., Spillmann, F., Westermann, D., Escher, F., Pauschinger, M., Pesquero, J. B., Bader, M., Schultheiss, H.-P., Noutsias, M. Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene.
Key Words: diabetes mellitus • diabetic cardiomyopathy • kallikrein • pathogenesis • therapy • transgenic animal
This article has been cited by other articles:
|
|
 |
|
  D. Westermann, T. Walther, K. Savvatis, F. Escher, M. Sobirey, A. Riad, M. Bader, H.-P. Schultheiss, and C. Tschope Gene Deletion of the Kinin Receptor B1 Attenuates Cardiac Inflammation and Fibrosis During the Development of Experimental Diabetic Cardiomyopathy Diabetes, June 1, 2009; 58(6): 1373 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, L. Ebermann, A. Sterner-Kock, S. Wika, H.-P. Schultheiss, A. Dorner, and T. Walther Myocardial overexpression of adenine nucleotide translocase 1 ameliorates diabetic cardiomyopathy in mice Exp Physiol, February 1, 2009; 94(2): 220 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Riad, S. Jager, M. Sobirey, F. Escher, A. Yaulema-Riss, D. Westermann, A. Karatas, M. M. Heimesaat, S. Bereswill, D. Dragun, et al. Toll-Like Receptor-4 Modulates Survival by Induction of Left Ventricular Remodeling after Myocardial Infarction in Mice J. Immunol., May 15, 2008; 180(10): 6954 - 6961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Van Linthout, F. Spillmann, A. Riad, C. Trimpert, J. Lievens, M. Meloni, F. Escher, E. Filenberg, O. Demir, J. Li, et al. Human Apolipoprotein A-I Gene Transfer Reduces the Development of Experimental Diabetic Cardiomyopathy Circulation, March 25, 2008; 117(12): 1563 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Fliegner, D. Westermann, A. Riad, C. Schubert, E. Becher, J. Fielitz, C. Tschope, and V. Regitz-Zagrosek Up-regulation of PPAR{gamma} in myocardial infarction Eur J Heart Fail, January 1, 2008; 10(1): 30 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Westermann, S. Van Linthout, S. Dhayat, N. Dhayat, F. Escher, C. Bucker-Gartner, F. Spillmann, M. Noutsias, A. Riad, H.-P. Schultheiss, et al. Cardioprotective and Anti-Inflammatory Effects of Interleukin Converting Enzyme Inhibition in Experimental Diabetic Cardiomyopathy Diabetes, July 1, 2007; 56(7): 1834 - 1841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Westermann, S. Rutschow, S. Jager, A. Linderer, S. Anker, A. Riad, T. Unger, H.-P. Schultheiss, M. Pauschinger, and C. Tschope Contributions of Inflammation and Cardiac Matrix Metalloproteinase Activity to Cardiac Failure in Diabetic Cardiomyopathy: The Role of Angiotensin Type 1 Receptor Antagonism Diabetes, March 1, 2007; 56(3): 641 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chandrashekhar Embracing Diversity in Remodeling: A Step in Therapeutic Decision Making in Heart Failure? J. Am. Coll. Cardiol., February 20, 2007; 49(7): 822 - 825. [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Gould, M. Yii, M. D. Esler, J. M. Power, and D. M. Kaye Atrial fibrillation impairs cardiac sympathetic response to baroreceptor unloading in congestive heart failure Eur. Heart J., December 1, 2005; 26(23): 2562 - 2567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. De Acetis, A. Notte, F. Accornero, G. Selvetella, M. Brancaccio, C. Vecchione, M. Sbroggio, F. Collino, B. Pacchioni, G. Lanfranchi, et al. Cardiac Overexpression of Melusin Protects From Dilated Cardiomyopathy Due to Long-Standing Pressure Overload Circ. Res., May 27, 2005; 96(10): 1087 - 1094. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
